{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:39:03Z","timestamp":1790836743269,"version":"4.1.0"},"reference-count":53,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatitis delta virus (HDV) infection is a defective virus requiring hepatitis B virus (HBV) for its complete replication cycle. HDV is a small hepatotropic RNA virus and around 15 to 25 million people worldwide are living with chronic hepatitis delta (CHD) infection. However, the prevalence of HDV may be underestimated, and screening is frequently insufficient. HDV infection remains endemic in several regions including Central and West Africa, the Mediterranean basin, the Middle East, Eastern Europe, Northern Asia, certain areas of Southeast Asia and the Amazon basin of South America. The best preventive strategy to decrease HDV infection is to improve coverage of the prophylactic HBV vaccine. HDV infection may occur by HBV\u2010HDV co\u2010infection or superinfection, and the latter is usually more severe. CHD is associated with a higher risk of cirrhosis and hepatocellular carcinoma (HCC) compared to HBV mono\u2010infection. Pegylated interferon alpha (PEG\u2010IFN\u03b1) therapy is limited by moderate effectiveness (around 20%) and its adverse effects. The entry inhibitor, bulevirtide (BLV, Hepcludex\n                    <jats:sup>\u00ae<\/jats:sup>\n                    ), which was recently approved in Europe at a dose of 2\u00a0mg in sub\u2010cutaneous injection per day, is indicated for the treatment of CHD in adult patients with compensated liver disease and positive HDV viremia. BLV can be administrated in monotherapy or in combination with PEG\u2010IFN\u03b1. Nucleos(t)ide analogues can be used in combination for underlying HBV infection. The optimal treatment duration has not yet been determined and treatment should be continued if a clinical benefit is observed. There are other promising therapies such as IFN lambda (IFN\u03bb) (immunomodulator), lonafarnib (prenylation inhibitor) and nucleic acid polymers (Inhibitors of HBsAg release). In this review, we will present an update on CHD and future promising treatments.\n                  <\/jats:p>","DOI":"10.1111\/liv.14838","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T01:38:49Z","timestamp":1624325929000},"page":"30-37","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["New therapies for hepatitis delta virus infection"],"prefix":"10.1111","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7860-8636","authenticated-orcid":false,"given":"Dimitri","family":"Loureiro","sequence":"first","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Castelnau","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-3489","authenticated-orcid":false,"given":"Issam","family":"Tout","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Boyer","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Narguet","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Menasria Benazzouz","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina","family":"Louis","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Service de Pharmacie AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Pons\u2010Kerjean","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Service de Pharmacie AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Giuly","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8950-0287","authenticated-orcid":false,"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3856-5771","authenticated-orcid":false,"given":"Abdellah","family":"Mansouri","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-0595","authenticated-orcid":false,"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9 de Paris Inserm CNRS Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.18.12.997"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.67.12.7659-7662.1993"},{"key":"e_1_2_12_4_1","unstructured":"Minist\u00e8re des Solidarit\u00e9s et de la sant\u00e9.11 vaccins obligatoires depuis 2018. Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9. Published July 11 2017. Accessed January 8 2021.https:\/\/solidarites\u2010sante.gouv.fr\/prevention\u2010en\u2010sante\/preserver\u2010sa\u2010sante\/vaccination\/vaccins\u2010obligatoires\/article\/11\u2010vaccins\u2010obligatoires\u2010depuis\u20102018"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14357"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.008"},{"key":"e_1_2_12_7_1","unstructured":"WHO | Global hepatitis report.WHO;2017. Accessed October 30 2020.http:\/\/www.who.int\/hepatitis\/publications\/global\u2010hepatitis\u2010report2017\/en\/"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316601"},{"key":"e_1_2_12_9_1","unstructured":"Hepatitis D. WHO | Hepatitis D. Accessed December 10 2020.https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/hepatitis\u2010d"},{"key":"e_1_2_12_10_1","unstructured":"GordienE.L\u2019infection par le virus de l\u2019h\u00e9patite Delta. Donn\u00e9es fran\u00e7aise r\u00e9centes \u2010 Bulletin \u00e9pid\u00e9miologique hebdomadaire. Accessed January 7 2021.http:\/\/beh.santepubliquefrance.fr\/beh\/2015\/19\u201020\/2015_19\u201020_3.html"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02277-06"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.06.038"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.8.3920-3927.2002"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058340"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.02.007"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.232416799"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/380454a0"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.19.8490"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.09.058"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240201"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401133300202"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.017"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21325"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912696"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30663-7"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix656"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.12.022"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.013"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14356"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.12.008"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.090"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.15.9786-9798.2005"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.3.1613-1622.2005"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24758"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30141-0"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3206"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.003"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1598578"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29658"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30464-6"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30310-0"},{"key":"e_1_2_12_43_1","first-page":"910A","article-title":"Exploring optimal dosing of lonafarnib with ritonavir for the treatment of chronic delta hepatitis\u2010interim results from the Lowr Hdv\u20102 study","volume":"64","author":"Yurdaydin C","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.9.4501-4509.2006"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.12.018"},{"key":"e_1_2_12_46_1","unstructured":"EtzionO HamidS LurieY et al.End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post\u2010treatment with pegylated interferon lambda monotherapy in patients with chronic HDV infection. 17."},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.058"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.020"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.037"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30190-6"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13673"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13656"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12403"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12565"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14838","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.14838","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T04:33:25Z","timestamp":1693283605000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.14838"}},"subtitle":[],"editor":[{"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":53,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/liv.14838"],"URL":"https:\/\/doi.org\/10.1111\/liv.14838","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2021-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}